Universidad Católica de Chile, Unidad de Cuidados Intensivos, Marcoleta 367, 8330024 Santiago, Chile.
J Trauma Acute Care Surg. 2012 May;72(5):1228-37; discussion 1237-8. doi: 10.1097/TA.0b013e318248bc6c.
The effectiveness of a single 6-hour session of high-volume hemofiltration (HVHF) was evaluated in terms of decreased norepinephrine (NE) requirements, progressive refractory hypotension and hypoperfusion by the fourth hour, and observed versus expected hospital mortality in patients with refractory severe septic shock.
A prospective cohort study conducted at the intensive care unit with 31 patients suffering from severe septic shock (NE dose ≥ 0.3 μg kg min to maintain mean arterial pressure 70-80 mm Hg and lactic acidosis) and refractory to treatments recommended by Surviving Sepsis Campaign, 2008. All patients were subjected to a single short-term 6-hour HVHF with a goal-directed protocol. Changes in NE dose, hemodynamic, metabolic, and respiratory parameters were measured at the onset (t0), 4 (t4) and 6 hours (t6) during HVHF. Patients were considered responders if by t4 of HVHF, they showed a decrease in NE dose ≥ 50%, maintaining mean arterial pressure 80 mm Hg to 70 mm Hg.
: Twenty-five of the 31 patients responded to HVHF treatment (responders), whereas 6 did not (nonresponders). In the responders group, a decrease in NE dose was observed by t4 (1.3 ± 0.5 μg kg min). This beneficial effect was maintained by t6 of treatment. Hemodynamic, metabolic, and respiratory parameters and other organic function indicators were also significantly improved by t4 and maintained by t6. Hospital mortality (45.16%) was significantly lower than that predicted by Sequential Organ Failure Assessment score (>90%): 83% for nonresponders versus 36% for responders.
We conclude that a single session of short-term 6-hour HVHF in patients with refractory severe septic shock reduces NE dose requirements and improves organic function already by the fourth hour of treatment.
III, therapeutic study.
评估了单次 6 小时高容量血液滤过(HVHF)治疗在减少去甲肾上腺素(NE)需求、第四小时时出现的进行性难治性低血压和低灌注、以及观察到的与难治性严重脓毒症休克患者预期死亡率方面的效果。
在重症监护病房进行的前瞻性队列研究,纳入 31 名患有严重脓毒症休克(NE 剂量≥0.3μg/kg/min 以维持平均动脉压 70-80mmHg 和乳酸酸中毒)且对 2008 年拯救脓毒症运动推荐的治疗无效的患者。所有患者均接受单次短期 6 小时 HVHF 治疗,采用目标导向方案。在 HVHF 开始时(t0)、4 小时(t4)和 6 小时(t6)测量 NE 剂量、血流动力学、代谢和呼吸参数的变化。如果在 HVHF 的 t4 时,患者显示 NE 剂量降低≥50%,同时维持平均动脉压在 80mmHg 至 70mmHg,则认为患者对 HVHF 治疗有反应。
31 名患者中有 25 名(反应者)对 HVHF 治疗有反应,而 6 名(无反应者)无反应。在反应者组中,在 t4 时观察到 NE 剂量下降(1.3±0.5μg/kg/min)。这种有益的效果在治疗的 t6 时仍能维持。血流动力学、代谢和呼吸参数以及其他器官功能指标在 t4 时也显著改善,并在 t6 时得以维持。医院死亡率(45.16%)明显低于序贯器官衰竭评估评分预测值(>90%):无反应者为 83%,反应者为 36%。
我们得出结论,在难治性严重脓毒症休克患者中,单次 6 小时短期 HVHF 可降低 NE 剂量需求,并在治疗的第 4 小时即可改善器官功能。
III 级,治疗性研究。